Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on ... (erous enzymes that are now known to be r...)

Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29

Date:1/23/2009

erous enzymes that are now known to be regulated by S-nitrosylation. Accumulating evidence suggests that many disease states are associated with aberrant protein S-nitrosylation. Dr. Stamler's group also identified the enzyme responsible for bioactivation of nitroglycerin, the ability of red blood cells to dilate blood vessels and a role for nitric oxide in the human respiratory cycle.

Duke University and Johns Hopkins University has awarded Cordex an exclusive worldwide license to a portfolio of compounds targeting the redox-NO imbalance as a new therapeutic modality in the management of patients with heart failure disease. Dr. Stamler is a scientific consultant to Cordex.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 safety clinical trial in heart failure patients early in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
5. Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Cumberland Pharmaceuticals Appoints Lee Product Director
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
10. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

Post Your Comments:

(Date:12/17/2009)... 2010, puts healthcare cost control at the head of the list ... ... New York, NY (Vocus) December 17, 2009 -- ... in 2010, puts healthcare cost control at the head ... , , , , ,“Healthcare typically lags trends in the business ...

(Date:12/17/2009)... latest particle size distribution technologies, including the new C35 Atex, ... 2010. , ... (PRWEB) December 17, ... American Association of Pharmaceutical Scientists’ Annual Meeting, AAPS 2010 , ... 612 at AAPS 2010 to see the latest particle size ...

(Date:12/16/2009)... A discovery by scientists at the University of East ... that use domestic or agricultural waste to generate clean ... Proceedings of the National Academy of Sciences ... the mechanism by which some bacteria survive by ,breathing ... in the development of new microbe-based technologies such as ...

(Date:12/16/2009)... Dec. 16 Martek Biosciences Corporation (Nasdaq: ... fourth quarter and fiscal year ended October 31, 2009. ... 3% from $90.4 million in the fourth quarter of ... per diluted share, for the fourth quarter of fiscal ... $0.31 per diluted share, in last year,s fourth quarter. ...

[0] Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010,[0] Particle Size Distribution Technologies at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting 2010 [0] 'Rock-breathing' bacteria could generate electricity and clean up oil spills [0] Martek Announces Fourth Quarter and FY 2009 Financial Results

... , , , , ... gene silencing in eukaryotic cell culture by targeting complementary ... (RNAi), enables targeted gene , silencing in functional ... oligonucleotide synthesis service that includes a range of modifications , ...

... , , , , , ... QIAGEN GmbH, Hilden, Germany , ... genetic modification , of neuronal cells by delivery of either ... Krichevsky and Kosik reported silencing , of endogenous genes in ...

... , , , For transfection of cells with siRNA in RNAi procedures, , ... , , , , , ... Quick and easy setup , Ready-to-use reagent ... , , , , Principle , , , ...

Other Biology Technology:Custom and library siRNA for efficient gene silencing 2 Custom and library siRNA for efficient gene silencing 3 Custom and library siRNA for efficient gene silencing 4 Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 2 Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 3 Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 4 Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 5 Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent 6 TransMessenger Transfection Reagent 2 TransMessenger Transfection Reagent 3

Custom and library siRNA for efficient gene silencing Efficient DNA transfection of primary CNS neurons using TransMessenger , Transfection Reagent TransMessenger Transfection Reagent

(Date:12/17/2009)... to create both cheap and effective drugs for diseases ... vaccines has previously been the lack of adjuvants, substances ... been a major breakthrough in this area. The study, ... the December issue of the journal Vaccine . ... today for allergies, cancer, and autoimmune diseases are based ...

(Date:12/16/2009)... change in warmer water, according to an intriguing new ... more aggressive. , Experiments with two species of young ... the first time that some reef fish are either ... differences are even more marked as water temperatures rise. ... degrees may have only a small effect on some ...

(Date:12/16/2009)... its student travel award to attend the Biophysical Society,s ... San Francisco, California, February 20-24, 2010. The recipients of ... with priority given to those who will present a ... travel grant and will be recognized at a reception ... the Student Travel Award are: , , Katherine Alfieri, Haverford ...

[0] Major breakthrough may pave the way for therapeutic vaccines [0] Fish with attitude: Some like it hot [0] Biophysical Society announces winners of 2010 Student Travel Awards

... Yan Liu imagine and assemble intricate structures on a ... DNA molecule, a versatile building material offering near limitless ... issue of Science , Yan and Liu, researchers ... of Chemistry and Biochemistry, reveal for the first time ...

... genetic signature associated with Alzheimer,s disease, the leading ... elderly. The research, published by Cell Press in ... of Human Genetics , uses a powerful, high-resolution ... devastating neurodegenerative disorder. , Previous research linked ...

... in lung cancer, a team of international researchers has discovered ... that "silencing" of a single gene in lung cancer led ... to cancer development and progression. , In the January 1, ... the American Association for Cancer Research, they also report finding ...

Other Biology News:The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2 The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3 Scientists make strides toward defining genetic signature of Alzheimer's disease 2 In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2 In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3

The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes Scientists make strides toward defining genetic signature of Alzheimer's disease In lung cancer, silencing one crucial gene disrupts normal functioning of genome

...

Weinreb Linker...

Indoleamine 2,3-dioxygenase [IDO]...

E2F-5...

Biology Products:

Human Interferon (IFN) and Receptor, PCR Array for expression profiling from SuperArray Bioscience Weinreb Linker from ChemPep, Inc.Anti-Indoleamine 2,3-dioxygenase (IDO) Monoclonal Antibody, Unconjugated from CHEMICON Rabbit Anti-E2F-5 Polyclonal Antibody, Unconjugated from Spring Bioscience

Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on ...(erous enzymes that are now known to be r...)